JP2018516978A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516978A5 JP2018516978A5 JP2018511592A JP2018511592A JP2018516978A5 JP 2018516978 A5 JP2018516978 A5 JP 2018516978A5 JP 2018511592 A JP2018511592 A JP 2018511592A JP 2018511592 A JP2018511592 A JP 2018511592A JP 2018516978 A5 JP2018516978 A5 JP 2018516978A5
- Authority
- JP
- Japan
- Prior art keywords
- guide rna
- cas
- cas protein
- mutation
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021189812A JP2022031769A (ja) | 2015-05-16 | 2021-11-24 | 深部イントロン突然変異の遺伝子編集 |
| JP2024038537A JP7814430B2 (ja) | 2015-05-16 | 2024-03-13 | 深部イントロン突然変異の遺伝子編集 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562162720P | 2015-05-16 | 2015-05-16 | |
| US62/162,720 | 2015-05-16 | ||
| PCT/US2016/027987 WO2016186772A2 (en) | 2015-05-16 | 2016-04-15 | Gene editing of deep intronic mutations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189812A Division JP2022031769A (ja) | 2015-05-16 | 2021-11-24 | 深部イントロン突然変異の遺伝子編集 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516978A JP2018516978A (ja) | 2018-06-28 |
| JP2018516978A5 true JP2018516978A5 (enExample) | 2019-05-23 |
| JP6985250B2 JP6985250B2 (ja) | 2021-12-22 |
Family
ID=55809259
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511592A Active JP6985250B2 (ja) | 2015-05-16 | 2016-04-15 | 深部イントロン突然変異の遺伝子編集 |
| JP2021189812A Pending JP2022031769A (ja) | 2015-05-16 | 2021-11-24 | 深部イントロン突然変異の遺伝子編集 |
| JP2024038537A Active JP7814430B2 (ja) | 2015-05-16 | 2024-03-13 | 深部イントロン突然変異の遺伝子編集 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189812A Pending JP2022031769A (ja) | 2015-05-16 | 2021-11-24 | 深部イントロン突然変異の遺伝子編集 |
| JP2024038537A Active JP7814430B2 (ja) | 2015-05-16 | 2024-03-13 | 深部イントロン突然変異の遺伝子編集 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11896651B2 (enExample) |
| EP (1) | EP3298134B8 (enExample) |
| JP (3) | JP6985250B2 (enExample) |
| KR (2) | KR102584873B1 (enExample) |
| CN (3) | CN118879692A (enExample) |
| AU (2) | AU2016265255B2 (enExample) |
| CA (1) | CA2986021A1 (enExample) |
| ES (1) | ES2952598T3 (enExample) |
| IL (2) | IL296365A (enExample) |
| MX (2) | MX2017014665A (enExample) |
| PL (1) | PL3298134T3 (enExample) |
| PT (1) | PT3298134T (enExample) |
| RU (2) | RU2759335C2 (enExample) |
| SG (2) | SG10201910750WA (enExample) |
| WO (1) | WO2016186772A2 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| US11028388B2 (en) | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| US9938521B2 (en) | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
| US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| JP6756700B2 (ja) | 2014-03-18 | 2020-09-16 | ユニバーシティ オブ マサチューセッツ | 筋萎縮性側索硬化症を処置するためのｒＡＡＶベースの組成物および方法 |
| EP3981876A1 (en) | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
| EP3540061A1 (en) | 2014-04-02 | 2019-09-18 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating primary open angle glaucoma |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3221457B1 (en) | 2014-11-21 | 2019-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification using paired guide rnas |
| EP4019975A1 (en) | 2015-04-24 | 2022-06-29 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
| PL3298134T3 (pl) * | 2015-05-16 | 2023-09-18 | Genzyme Corporation | Edycja genów mutacji głęboko intronowych |
| US10662440B2 (en) | 2015-06-19 | 2020-05-26 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| EP3433364A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
| SG10202102885UA (en) | 2016-05-20 | 2021-05-28 | Regeneron Pharma | Methods for breaking immunological tolerance using multiple guide rnas |
| US11566263B2 (en) | 2016-08-02 | 2023-01-31 | Editas Medicine, Inc. | Compositions and methods for treating CEP290 associated disease |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| IT201600102542A1 (it) * | 2016-10-12 | 2018-04-12 | Univ Degli Studi Di Trento | Plasmide e sistema lentivirale contenente un circuito autolimitante della Cas9 che ne incrementa la sicurezza. |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| US9963719B1 (en) | 2016-12-05 | 2018-05-08 | Editas Medicine, Inc. | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| AU2018264996A1 (en) | 2017-05-09 | 2019-12-05 | University Of Massachusetts | Methods of treating Amyotrophic Lateral Sclerosis (ALS) |
| EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CN118006607A (zh) | 2017-09-22 | 2024-05-10 | 马萨诸塞大学 | Sod1双表达载体及其用途 |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3714055A1 (en) | 2017-11-21 | 2020-09-30 | CRISPR Therapeutics AG | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| IL277234B2 (en) | 2018-03-14 | 2026-03-01 | Editas Medicine Inc | Systems and methods for treating hemoglobin diseases |
| EP3768327A4 (en) * | 2018-03-23 | 2022-04-13 | The Trustees of Columbia University in the City of New York | GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES |
| CA3094828A1 (en) * | 2018-03-23 | 2019-09-26 | Massachusetts Eye And Ear Infirmary | Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome |
| EP3781174A4 (en) | 2018-04-09 | 2022-01-26 | Allen Institute | RESCUE OF VOLTAGE CONTROLLED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12492411B2 (en) | 2018-05-30 | 2025-12-09 | The Regents Of The University Of California | Gene editing of monogenic disorders in human hematopoietic stem cells—correction of X-linked agammaglobulinemia (XLA) |
| GB201809588D0 (en) * | 2018-06-12 | 2018-07-25 | Univ Bristol | Materials and methods for modulating intraocular and intracranial pressure |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020027982A1 (en) * | 2018-08-02 | 2020-02-06 | Editas Medicine, Inc. | Compositions and methods for treating cep290-associated disease |
| KR102158428B1 (ko) | 2018-08-16 | 2020-09-22 | (주)라트바이오 | 인위적 뉴클레아제를 생산하는 형질전환 배아 및 형질전환 동물의 제작 방법 |
| AU2019354296A1 (en) | 2018-10-01 | 2021-04-29 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating propionic acidemia |
| US12467064B2 (en) | 2018-10-08 | 2025-11-11 | Allen Institute | Artificial expression constructs for selectively modulating gene expression in interneurons |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| MX2021005997A (es) * | 2018-11-21 | 2021-08-11 | Vectores virales recombinantes y acidos nucleicos para producirlos. | |
| IT201800020230A1 (it) * | 2018-12-19 | 2020-06-19 | Univ Degli Studi Di Siena | Sistema CRISPR-Cas per la terapia genica. |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| EP3930694A1 (en) * | 2019-02-28 | 2022-01-05 | Regeneron Pharmaceuticals, Inc. | Adeno-associated virus vectors for the delivery of therapeutics |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| MX2021011782A (es) | 2019-03-27 | 2021-12-10 | Res Inst Nationwide Childrens Hospital | Generación de células nk primarias del receptor de antígeno quimérico (car) para la inmunoterapia al cáncer usando una combinación de virus cas9/rnp y aav. |
| KR20220004648A (ko) | 2019-03-28 | 2022-01-11 | 인텔리아 테라퓨틱스, 인크. | Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법 |
| KR20210113393A (ko) * | 2019-03-28 | 2021-09-15 | 주식회사 툴젠 | 혈액응고인자 viii 유전자 역위 보정에 의한 혈우병 치료용 조성물 |
| US20220298500A1 (en) * | 2019-04-15 | 2022-09-22 | The Trustees Of The University Of Pennsylvania | Compositions for regulating and self-inactivating enzyme expression and methods for modulating off-target activity of enzymes |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN111370055B (zh) * | 2020-03-05 | 2023-05-23 | 中南大学 | 内含子保留预测模型建立方法及其预测方法 |
| IL296662A (en) * | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| US12686874B2 (en) | 2020-03-31 | 2026-07-21 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating propionic acidemia |
| EP4143326A1 (en) | 2020-04-27 | 2023-03-08 | University of Iowa Research Foundation | Compositions and methods for the treatment of cystic fibrosis |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| AU2022216614B2 (en) | 2021-02-05 | 2026-03-05 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
| EP4301462A1 (en) * | 2021-03-04 | 2024-01-10 | Research Institute at Nationwide Children's Hospital | Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications |
| US20220325298A1 (en) * | 2021-04-12 | 2022-10-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Crispr epigenetic therapeutics for pain management |
| JP7780172B2 (ja) * | 2021-07-30 | 2025-12-04 | 国立研究開発法人理化学研究所 | 筋萎縮性側索硬化症におけるｃｅｐ２９０遺伝子の変異 |
| CN114306277B (zh) * | 2021-11-02 | 2023-08-04 | 中国人民解放军空军军医大学 | 一种靶向psma的巨噬细胞膜包裹的仿生纳米药物载体及应用 |
| EP4223877A1 (en) | 2022-02-08 | 2023-08-09 | Eberhard Karls Universität Tübingen Medizinische Fakultät | System and method for editing genomic dna to modulate splicing |
| WO2025135916A1 (ko) * | 2023-12-22 | 2025-06-26 | 주식회사 툴젠 | 낮은 면역원성을 가지는 cas9 단백질 변이체 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| SI1496944T1 (sl) | 2002-05-01 | 2009-02-28 | Univ Florida | Izboljšani sistemi ekspresije RAAV za genetsko modifikacijo specifičnih kapsidnih proteinov |
| JP4559429B2 (ja) | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法 |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| US7407801B2 (en) * | 2003-12-05 | 2008-08-05 | University Of Iowa Research Foundation | Truncated CMV promoters and vectors containing same |
| US7765583B2 (en) | 2005-02-28 | 2010-07-27 | France Telecom | System and method for managing virtual user domains |
| US8283151B2 (en) | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
| US7588772B2 (en) | 2006-03-30 | 2009-09-15 | Board Of Trustees Of The Leland Stamford Junior University | AAV capsid library and AAV capsid proteins |
| US20100081707A1 (en) | 2008-02-21 | 2010-04-01 | Ali Robin R | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| AU2009231171A1 (en) | 2008-04-02 | 2009-10-08 | Fondazione Telethon | Method of treating genetic disorders |
| JP5956331B2 (ja) | 2009-06-16 | 2016-07-27 | ジェンザイム・コーポレーション | 組換えａａｖベクターの改良された精製方法 |
| WO2012099540A1 (en) * | 2011-01-17 | 2012-07-26 | Agency For Science, Technology And Research | Cmv promoter variants |
| CN103502458B (zh) | 2011-02-17 | 2016-11-16 | 宾夕法尼亚大学托管会 | 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR20250012194A (ko) * | 2013-06-17 | 2025-01-23 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| ES2777217T3 (es) * | 2013-06-17 | 2020-08-04 | Broad Inst Inc | Suministro, modificación y optimización de sistemas de guía en tándem, métodos y composiciones para la manipulación de secuencias |
| CN111218447B (zh) * | 2013-11-07 | 2024-10-11 | 爱迪塔斯医药有限公司 | 使用统治型gRNA的CRISPR相关方法和组合物 |
| KR20160097338A (ko) | 2013-12-12 | 2016-08-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도 |
| US9938521B2 (en) * | 2014-03-10 | 2018-04-10 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10) |
| PL3298134T3 (pl) | 2015-05-16 | 2023-09-18 | Genzyme Corporation | Edycja genów mutacji głęboko intronowych |
| US10662440B2 (en) * | 2015-06-19 | 2020-05-26 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| WO2017136335A1 (en) * | 2016-02-01 | 2017-08-10 | The Regents Of The University Of California | Self-inactivating endonuclease-encoding nucleic acids and methods of using the same |
-
2016
- 2016-04-15 PL PL16718840.8T patent/PL3298134T3/pl unknown
- 2016-04-15 KR KR1020177036029A patent/KR102584873B1/ko active Active
- 2016-04-15 JP JP2018511592A patent/JP6985250B2/ja active Active
- 2016-04-15 KR KR1020237033136A patent/KR20230142649A/ko active Pending
- 2016-04-15 EP EP16718840.8A patent/EP3298134B8/en active Active
- 2016-04-15 ES ES16718840T patent/ES2952598T3/es active Active
- 2016-04-15 CN CN202410714061.8A patent/CN118879692A/zh active Pending
- 2016-04-15 SG SG10201910750WA patent/SG10201910750WA/en unknown
- 2016-04-15 RU RU2017143997A patent/RU2759335C2/ru active
- 2016-04-15 CA CA2986021A patent/CA2986021A1/en active Pending
- 2016-04-15 PT PT167188408T patent/PT3298134T/pt unknown
- 2016-04-15 CN CN201680041691.7A patent/CN107849547B/zh active Active
- 2016-04-15 SG SG10201912907PA patent/SG10201912907PA/en unknown
- 2016-04-15 CN CN202210293007.1A patent/CN114657180A/zh active Pending
- 2016-04-15 US US15/574,420 patent/US11896651B2/en active Active
- 2016-04-15 WO PCT/US2016/027987 patent/WO2016186772A2/en not_active Ceased
- 2016-04-15 IL IL296365A patent/IL296365A/en unknown
- 2016-04-15 RU RU2021132397A patent/RU2021132397A/ru unknown
- 2016-04-15 MX MX2017014665A patent/MX2017014665A/es unknown
- 2016-04-15 AU AU2016265255A patent/AU2016265255B2/en active Active
-
2017
- 2017-11-14 IL IL255654A patent/IL255654B2/en unknown
- 2017-11-15 MX MX2023006046A patent/MX2023006046A/es unknown
-
2021
- 2021-11-24 JP JP2021189812A patent/JP2022031769A/ja active Pending
-
2022
- 2022-06-16 AU AU2022204199A patent/AU2022204199B2/en active Active
-
2023
- 2023-12-28 US US18/399,364 patent/US20240197837A1/en active Pending
-
2024
- 2024-03-13 JP JP2024038537A patent/JP7814430B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017143997A (ru) | Генное редактирование глубоких интронных мутаций | |
| JP7561788B2 (ja) | 臨床使用に適した無血清懸濁細胞培養システムにおいて組換えアデノ随伴ウイルス（ａａｖ）ベクターを産生するスケーラブルな方法 | |
| CN105579465B (zh) | 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途 | |
| JP2022529424A5 (enExample) | ||
| JP2020500541A5 (enExample) | ||
| JP2024099770A5 (enExample) | ||
| JP2021511803A5 (enExample) | ||
| JP2022529631A5 (enExample) | ||
| IL292999A (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
| US11814642B2 (en) | Manufacturing and use of recombinant AAV vectors | |
| JP2024519469A5 (enExample) | ||
| JP2021534814A5 (enExample) | ||
| CN116194152A (zh) | 用于改进封闭端DNA（ceDNA）的产生的经修饰的杆状病毒系统 | |
| WO2020142714A1 (en) | Aav expression cassette and aav vectors comprising the same | |
| IL292605A (en) | CRISPR and AAV strategies for the treatment of x-linked childhood retinoschisis | |
| JP2020509786A5 (enExample) | ||
| EP3943512A1 (en) | Fusion protein for enhancing gene editing and use thereof | |
| US20210261982A1 (en) | Raav-mediated nuclease-associated vector integration (raav-navi) | |
| WO2025137123A1 (en) | Compositions and methods for circularizing donor nucleic acids | |
| Feng et al. | A 16 bp Rep binding element is sufficient for mediating Rep-dependent integration into AAVS1 | |
| US20250019667A1 (en) | Adenoviral helper plasmid | |
| WO2018204626A1 (en) | Regulatable gene editing compositions and methods | |
| CN115605266A (zh) | Dysferlin双载体的基因疗法 | |
| JP2025515030A5 (enExample) | ||
| CN120359235A (zh) | 用于治疗心脏病和与心脏功能障碍相关的疾病的具有降低的肝脏嗜性和增强的心脏细胞转导的重组腺相关病毒基因治疗载体 |